. Author manuscript; available in PMC: 2013 Apr 10.

Published in final edited form as: Pract Radiat Oncol. 2011 Aug 3;2(2):77–85. doi: 10.1016/j.prro.2011.06.009

Table 7.

Prior studies identifying prognostic factors for locally advanced pancreatic cancer

Authors	Group / Institution	No. of Patients	Range of treatment dates	Treatment	Poor prognostic factors for OS	Poor prognostic factors for PFS
Klaasen et al¹ (1985)	ECOG	91	1974–1984	5FU-based CRT, maintenance 5FU chemo	ECOG <2, Broder’s grade <3, reduced appetite	Not performed
Ikeda et al¹² (2001)	NCCH	55	1993–1998	5FU or cisplatin-based CRT	ECOG <2, CA19-9 >1000, regional node swelling	Not performed
Krishnan et al¹⁹ (2007)	MDACC	247	1993–2005	5FU capecitabine, or gemcitabine-based CRT	KPS ≤80, Hgb <12	KPS ≤80
Huang et al¹³ (2009)	NYMUSM	55	2002–2005	Gemcitabine-based CRT	KPS ≤80, CA19-9 >1000	KPS ≤80, CA19-9 >1000
Current study	JHU	109	1997–2009	5FU or gemcitabine- based CRT	KPS ≤80, treatment break, local disease status	KPS ≤80, CA19-9 >1000, treatment break

CRT, chemoradiation; ECOG, Eastern Cooperative Oncology Group; JHU, Johns Hopkins University; KPS, Karnofsky performance status; NCCHT, National Cancer Center Hospital of Tokyo; MDACC, M.D. Anderson Cancer Center; NYMUSM, National Yang-Ming University School of Medicine; PFS, progression-free survival; OS, overall survival.